| In
a blind and randomized, Placebo controlled clinical trial the effect of PulmoFlex
(400 mg) was studied on allergic reactions typical for bronchial asthma. A remarkable
decrease in the plasma level of leukotrienes in the group A (PulmoFlex) was observed
in 13 out of 21 patients whereas in group B (Placebo) the decrease was statistically
not significant. After treatment 19 patients of group A (PulmoFlex) did not have
any complaint, no adverse reaction was reported. In Placebo group (B) 44.4% patients
had some change for the worse. In 17 (80.95%) of PulmoFlex treated cases the attacks
of asthma disappeared and in the remaining they were significantly reduced. After
treatment with PulmoFlex in around 50% of cases dyspnea attacks stopped. In Placebo
group the curative effect was absent. In cases with mild to moderate asthma, in
the periods of unstable remission, PulmoFlex can be a basic remedy which prevents
the obstruction of bronchus and is also useful for bronchial drainage. LTs in
asthma pathogenesis are responsible for duration of respiratory dyspnea attacks
depending on prolonged bronchospasm which may be resistant to B2 agonist. In acute
or severe conditions, oral administration of PulmoFlex as a basic remedy, in combination
with B2 agonists can be very useful, to prevent the occurrence of asthmatic attacks
and to help reduce the frequency of B2 agonists inhalations as well as to prevent
the side effects associated with their regular and prolonged use.
A.G.
Panossian et. al. (1998), Armenia, XIIIth international Congress of Pharmacology,
1998 at Munchen, Germany.
Alleviation of
breathlessness and quality of life improved with 8-10 days of PulmoFlex administration.
PulmoFlex acts through axon reflexes and neuropeptides in relieving coughs and
through leukotriene pathway in alleviating broncho-constriction. PulmoFlex alleviated
the cough and broncho-spasm through separate pathways while in some it blocked
both the pathways. PulmoFlex which was found effective in "Difficult Asthma"
designated in "Step-4" Group by WHO, was tried in children of either
sex between 5-13 years of age, in recommended dose for 5-7 months. These children
had stable mild persistent (Step-2) or moderate persistent (Step-3) Asthama and
elevated serum lgE levels. The formulation was tolerated well, no drop out was
seen and remarkable alleviation of cough was observed. Significant decrease in
the number of Beta-2 agonist inhalations was seen with improvement in FEV. Serum
lgE decrease was also significant in six cases. These findings suggest the effective
role of PULMOFLEX in management of childhood asthma.
Vijay
K. Singh (1996), Patel Chest Institute, Unviersity of Delhi, Indian J. Indg. Med.
18(1) : 29-34 and 18(2) : 87-93.
PulmoFlex
in a dose of 2 capsules daily for 2 weeks in 20 patients with Perennial Allergic
Rhinitis was found useful as a potent and highly effective treatment. TLC from
a mean of 9833 per Cu mm before treatment came down to 7650 per Cu mm at the end
of 2 weeks treatment. Similarly ESR from an average high of 27 mm (for 1st hour)
came down to 14 mm, Lymphocyte count increased from a mean value of 13% to 19.66%
registering 51.23% improvement. Antihistamines like Cetrizine and Intranasal injection
of Hydrocortisone acetate show variable improvement in symptoms which does not
last long and treatment has to be repeated very often. PulmoFlex offers long lasting
benefit and is free from side effects caused by antihistamines and local corticosteroid
usage.
Mathur
A.K. et. al. (1996). Paper presented at the XXIX IPS conference December 20-22,
1996, Hyderabad.
A clinical trial was conducted
in 44 patients suffering from bronchial asthma. The patients were gradually switched
over to herbal PulmoFlex from complex allopathic medicines i.e. Theophyline and
Salbutamol. The subjects under trial showed significant clinical recovery. Haematological
and Lung Function Tests indicated beneficial effects of PulmoFlex against allergic
bronchial asthma. Eosinophilia was reduced significantly in the patients under
trial which eventually protected them from Late Asthmatic Response (LAR). The
present study indicates the excellent therapeutic efficacy of PulmoFlex against
bronchial asthma. Bhusan Kumar and
Munish Sawhney (1996). A.K. et. al. (1996). Indian J. Indg. Med. 18(1) : 35-39. | 